akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347/ob.gyn.rep.2022.363akusherstvo-1465Research ArticleREVIEW ARTICLESНАУЧНЫЕ ОБЗОРЫPrognostic value of von Willebrand factor in clinical practiceПрогностическое значение фактора фон Виллебранда в клинической практикеhttps://orcid.org/0000-0002-7756-8935ГригорьеваК. Н.GrigorevaK. N.

Григорьева Кристина Николаевна – ассистент кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Kristina N. Grigoreva – MD, Assistant, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

grigkristik96@gmail.comhttps://orcid.org/0000-0001-8404-1042БицадзеВ. О.BitsadzeV. O.

Бицадзе Виктория Омаровна – д.м.н., профессор РАН, профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. ФилатоваScopus Author ID: 6506003478Researcher ID: F-8409-2017

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Victoria O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s HealthScopus Author ID: 6506003478Researcher ID: F-8409-2017

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

https://orcid.org/0000-0002-0725-9686ХизроеваД. Х.KhizroevaJ. Kh.

Хизроева Джамиля Хизриевна – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. ФилатоваScopus Author ID: 57194547147Researcher ID: F-8384-2017

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Jamilya Kh. Khizroeva – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s HealthScopus Author ID: 57194547147Researcher ID: F-8384-2017

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

https://orcid.org/0000-0001-5888-0774ЦибизоваВ. И.TsibizovaV. I.

Цибизова Валентина Ивановна – к.м.н., врач акушер-гинеколог НИЛ оперативной гинекологии Института перинатологии и педиатрии, врач отделения функциональной ультразвуковой диагностики

197341 Санкт-Петербург, ул. Аккуратова, д. 2

Valentina I. Tsibizova – MD, PhD, Obstetrician-Gynecologist, Research Laboratory of Operative Gynecology, Institute of Perinatology and Pediatrics; Physician, Department of Functional and Ultrasound Diagnostics

197341, Saint Petersburg, Akkuratova Str., 2

https://orcid.org/0000-0002-3628-0804ТретьяковаМ. В.TretyakovaM. V.

Третьякова Мария Владимировна – к.м.н., врач акушер-гинеколог, ассистент кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Maria V. Tretyakova – MD, PhD, Obstetrician-Gynecologist, Assistant, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

https://orcid.org/0000-0002-3367-9844БлиновД. В.BlinovD. V.

Блинов Дмитрий Владиславович – к.м.н., руководитель по медицинским и научным вопросам, Институт Превентивной и Социальной Медицины; врач-невролог, Клинический Госпиталь Лапино, ГК «Мать и Дитя»Scopus Author ID: 6701744871Researcher ID: E-8906-2017RSCI: 9779-8290

127006 Москва, ул. Садовая-Триумфальная, д. 4–10143081 Московская область, Одинцовский район, Лапино, 1-е Успенское шоссе, д. 111

Dmitry V. Blinov – MD, PhD, MBA, Head of Medical and Scientific Affairs, Institute for Preventive and Social Medicine; Neurologist, Lapino Clinical Hospital, MD Medical GroupScopus Author ID: 6701744871Researcher ID: E-8906- 2017RSCI: 9779-8290

127006, Moscow, Sadovaya-Triumfalnaya Str., 4–10143081, Moscow region, Odintsovo District, Lapino, 1st Uspenskoe Highway, 111

https://orcid.org/0000-0002-1339-4155ПанкратьеваЛ. Л.PankratyevaL. L.

Панкратьева Людмила Леонидовна – д.м.н., руководитель научно-клинического центра ГБУЗ «Городская клиническая больница № 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»; врач-неонатолог, врач-гематолог, доцент, профессор кафедры педиатрии и организации здравоохранения ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева»Scopus Author ID: 7006391091Author ID: 697284

123423 Москва, ул. Саляма Адиля, д. 2/44117997 Москва, ул. Саморы Машела, д. 1

Liudmila L. Pankratyeva – MD, Dr Sci Med, Head of the Clinical Research Center, Vorokhobov City Clinical Hospital № 67; Neonatologist, Hematologist, Associate Professor, Professor, Department of Pediatrics and Health Organization, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and ImmunologyScopus Author ID: 7006391091Author ID: 697284

123423, Moscow, Salyama Adilya Str., 2/44117997, Moscow, Samora Machel Str., 1

https://orcid.org/0000-0003-0764-4477ГашимоваН. Р.GashimovaN. R.

Гашимова Нилуфар Рамиль кызы – аспирант кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Nilufar R. Gashimova – MD, Postgraduate Student, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

https://orcid.org/0000-0002-8882-1588ЯкубоваФ. Э.YakubovaF. E.

Якубова Фидан Эльчин кызы – клинический ординатор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Fidan E. Yakubova – MD, Clinical Resident, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children's Health

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

fi_dan_2017@mail.ruhttps://orcid.org/0000-0002-4534-2157АнтоноваА. С.AntonovaA. S.

Антонова Александра Сергеевна – ассистент кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Alexandra S. Antonova – MD, Assistant, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

https://orcid.org/0000-0002-9899-9910ГриЖ.-К.GrisJ.-C.

Гри Жан-Кристоф – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); профессор гематологии, университет Монпелье; иностранный член РАНResearcher ID: AAA-2923-2019

119991 Москва, ул. Большая Пироговская, д. 2, стр. 434090, Франция, Монпелье, ул. Огюста Бруссоне, д. 163

Jean-Christophe Gris – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health, Sechenov University; University of Montpellier, Montpellier, France; Foreign Member of RASResearcher ID: AAA-2923-2019

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 434090, France, Montpellier, Rue Auguste Broussonnet, 163

https://orcid.org/0000-0002-9576-1368ЭлаламиИ.ElalamyI.

Элалами Исмаил – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); профессор медицинского Университета Сорбонны; директор гематологии Центра Тромбозов, Госпиталь ТенонScopus Author ID: 7003652413Researcher ID: AAC-9695-2019

119991 Москва, ул. Большая Пироговская, д. 2, стр. 475006, Франция, Париж, Улица медицинского факультета, д. 1275020, Франция, Париж, Китайская улица, д. 4

Ismail ElalamyScopus Author ID: 7003652413Researcher ID: AAC-9695-2019

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 475006, France, Paris, Rue de l’École de Médecine, 1275020, France, Paris, Rue de la Chine, 4

https://orcid.org/0000-0001-7415-4633МакацарияА. Д.MakatsariyaA. D.

Макацария Александр Давидович – д.м.н., профессор, академик РАН, зав. кафедрой акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. ФилатоваScopus Author ID: 57222220144Researcher ID: M-5660-2016

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Alexander D. Makatsariya – MD, Dr Sci Med, Academician of RAS, Professor, Head of the Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health, Sechenov UniversityScopus Author ID: 57222220144Researcher ID: M-5660-2016

119991, Moscow, Bolshaya Pirogovskaya Str., 2 bldg. 4

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияSechenov UniversityRussian FederationФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre, Health Ministry of Russian FederationRussian FederationИнститут Превентивной и Социальной Медицины; Клинический Госпиталь Лапино, ГК «Мать и Дитя»РоссияInstitute for Preventive and Social Medicine; Lapino Clinic Hospital, MD Medical GroupRussian FederationГБУЗ «Городская клиническая больница № 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»; ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Министерства здравоохранения Российской ФедерацииРоссияVorokhobov City Clinical Hospital № 67, Moscow Healthcare Department; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Health Ministry of Russian FederationRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Университет МонпельеРоссияSechenov University; University of MontpellierRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Медицинский Университет Сорбонны; Госпиталь ТенонРоссияSechenov University; Medicine Sorbonne University; Hospital TenonRussian Federation202204112022165588599Copyright © Grigoreva K.N., Bitsadze V.O., Khizroeva J.K., Tsibizova V.I., Tretyakova M.V., Blinov D.V., Pankratyeva L.L., Gashimova N.R., Yakubova F.E., Antonova A.S., Gris J., Elalamy I., Makatsariya A.D., 20222022Григорьева К.Н., Бицадзе В.О., Хизроева Д.Х., Цибизова В.И., Третьякова М.В., Блинов Д.В., Панкратьева Л.Л., Гашимова Н.Р., Якубова Ф.Э., Антонова А.С., Гри Ж., Элалами И., Макацария А.Д.Grigoreva K.N., Bitsadze V.O., Khizroeva J.K., Tsibizova V.I., Tretyakova M.V., Blinov D.V., Pankratyeva L.L., Gashimova N.R., Yakubova F.E., Antonova A.S., Gris J., Elalamy I., Makatsariya A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/1465

The von Willebrand factor (vWF) is a multimeric plasma glycoprotein, which quantification has important prognostic value. The current literature review demonstrates a relationship between the disease severity and vWF level. For example, von Willebrand disease is characterized by a quantitative/qualitative genetic vWF deficiency resulting in potentially developed massive bleeding, which knowledge can prevent development of formidable complications. We should also not forget about an opportunity of developing acquired Willebrand syndrome most often occurring in response to autoimmune diseases. A marked vWF increase during pregnancy may evidence about developing preeclampsia, whereas in newborns exposed to additional risk factors, it can lead to thrombosis. In cancer patients, a substantially elevated vWF level correlates with low survival, especially in those with ovarian cancer, glioblastomas, esophageal and lung cancer. The emergence of a novel coronavirus infection COVID-19 allowed us to take a fresh look at prognostic value of vWF, because numerous studies show that increased blood plasma vWF:Ag is associated with more adverse outcome in patients with COVID-19. Here, we demonstrate an importance of determining vWF level, because early diagnostics and treatment can improve the outcomes of all such patients.

Фактор фон Виллебранда (англ. von Willebrand factor, vWF) является мультимерным гликопротеином плазмы, определение которого имеет важное прогностическое значение. В данном литературном обзоре показана взаимосвязь между тяжестью заболеваний и уровнем vWF. Так, например, болезнь Виллебранда характеризуется количественным/качественным генетическим дефицитом vWF, вследствие чего может развиться массивное кровотечение, и знание этого может предупредить развитие грозных осложнений. Не стоит также забывать о возможности развития приобретенного синдрома Виллебранда, который чаще всего возникает в ответ на аутоиммунные заболевания. Существенное повышение уровня vWF в крови во время беременности может свидетельствовать о развитии преэкламспии, а у новорожденных при воздействии дополнительных факторов риска может приводить к тромбозам. У онкологических больных значительное повышение уровня vWF коррелирует с низкой выживаемостью, особенно у пациентов с раком яичников, глиобластомами, раком пищевода и легких. Возникновение новой коронавирусной инфекции COVID-19 позволило по-новому взглянуть на прогностическое значение vWF: так, многочисленные исследования показывают, что повышение в плазме крови vWF:Ag связано с более неблагоприятными исходами у пациентов с COVID-19. В данной статье показана значимость определения уровня vWF, так как ранняя диагностика и лечение смогут улучшить исходы всех этих пациентов. 

фактор фон ВиллебрандаvWFметаллопротеаза ADAMTS-13vWF/ADAMTS-13болезнь Виллебрандасистема гемостазаvon Willebrand factorvWFADAMTS-13 metalloproteasevWF/ADAMTS-13von Willebrand diseasehemostasisReferencesZhou Y.-F., Eng E.T., Zhu J. et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449–58. https://doi.org/10.1182/blood-2012-01-405134.Zhou Y.-F., Eng E.T., Zhu J. et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449–58. https://doi.org/10.1182/blood-2012-01-405134.Nightingale T., Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost. 2013;11 Suppl 1(Suppl 1):192–201. https://doi.org/10.1111/jth.12225.Nightingale T., Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost. 2013;11 Suppl 1(Suppl 1):192–201. https://doi.org/10.1111/jth.12225.Valentijn K.M., Sadler J.E., Valentijn J.A. et al. Functional architecture of Weibel-Palade bodies. Blood. 2011;117(19):5033–43. https://doi.org/10.1182/blood-2010-09-267492.Valentijn K.M., Sadler J.E., Valentijn J.A. et al. Functional architecture of Weibel-Palade bodies. Blood. 2011;117(19):5033–43. https://doi.org/10.1182/blood-2010-09-267492.Lenting P.J., Christophe O.D., Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019–28. https://doi.org/10.1182/blood-2014-06-528406.Lenting P.J., Christophe O.D., Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019–28. https://doi.org/10.1182/blood-2014-06-528406.De Ceunynck K., De Meyer S.F., Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121(2):270–7. https://doi.org/10.1182/blood-2012-07-442285.De Ceunynck K., De Meyer S.F., Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121(2):270–7. https://doi.org/10.1182/blood-2012-07-442285.Wieberdink R.G., van Schie M.C., Koudstaal P.J. et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151–6. https://doi.org/10.1161/STROKEAHA.110.586289.Wieberdink R.G., van Schie M.C., Koudstaal P.J. et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151–6. https://doi.org/10.1161/STROKEAHA.110.586289.Rietveld I.M., Lijfering W.M., le Cessie S. et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost. 2019;17(1):99–109. https://doi.org/10.1111/jth.14343.Rietveld I.M., Lijfering W.M., le Cessie S. et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost. 2019;17(1):99–109. https://doi.org/10.1111/jth.14343.Bowman M., Hopman W.M., Rapson D. et al. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213–6. https://doi.org/10.1111/j.1538-7836.2009.03661.x.Bowman M., Hopman W.M., Rapson D. et al. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213–6. https://doi.org/10.1111/j.1538-7836.2009.03661.x.Von Willebrand E.A. Hereditary pseudohaemophilia. Haemophilia. 1999;5(3):223–31; discussion 222. https://doi.org/10.1046/j.1365-2516.1999.00302.x.Von Willebrand E.A. Hereditary pseudohaemophilia. Haemophilia. 1999;5(3):223–31; discussion 222. https://doi.org/10.1046/j.1365-2516.1999.00302.x.Verweij C.L., Diergaarde P.J., Hart M., Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5(8):1839–47.Verweij C.L., Diergaarde P.J., Hart M., Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5(8):1839–47.Sadler J.E. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395–424. https://doi.org/10.1146/annurev.biochem.67.1.395.Sadler J.E. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395–424. https://doi.org/10.1146/annurev.biochem.67.1.395.Mannucci P.M. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351(7):683–94. https://doi.org/10.1056/NEJMra040403.Mannucci P.M. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351(7):683–94. https://doi.org/10.1056/NEJMra040403.James A.H., Kouides P.A., Abdul-Kadir R. et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124–34. https://doi.org/10.1016/j.ejogrb.2011.04.025.James A.H., Kouides P.A., Abdul-Kadir R. et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124–34. https://doi.org/10.1016/j.ejogrb.2011.04.025.Govorov I., Ekelund L., Chaireti R. et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease. Exp Ther Med. 2016;11(5):1923–9. https://doi.org/10.3892/etm.2016.3144.Govorov I., Ekelund L., Chaireti R. et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease. Exp Ther Med. 2016;11(5):1923–9. https://doi.org/10.3892/etm.2016.3144.Lavin M., Aguila S., Dalton N. et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784–91. https://doi.org/10.1182/bloodadvances.2018017418.Lavin M., Aguila S., Dalton N. et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784–91. https://doi.org/10.1182/bloodadvances.2018017418.Nowak-Göttl U., Limperger V., Kenet G. et al. Developmental hemostasis: a lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cells Mol Dis. 2017;67:2–13. https://doi.org/10.1016/j.bcmd.2016.11.012.Nowak-Göttl U., Limperger V., Kenet G. et al. Developmental hemostasis: a lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cells Mol Dis. 2017;67:2–13. https://doi.org/10.1016/j.bcmd.2016.11.012.James A.H., Konkle B.A., Kouides P. et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015;21(1):81–7. https://doi.org/10.1111/hae.12568.James A.H., Konkle B.A., Kouides P. et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015;21(1):81–7. https://doi.org/10.1111/hae.12568.James A.H., Jamison M.G. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5(6):1165–9. https://doi.org/10.1111/j.1538-7836.2007.02563.x.James A.H., Jamison M.G. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5(6):1165–9. https://doi.org/10.1111/j.1538-7836.2007.02563.x.Majluf-Cruz K., Anguiano-Robledo L., Calzada-Mendoza C.C. et al. von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage. Haemophilia. 2020;26(1):97–105. https://doi.org/10.1111/hae.13900.Majluf-Cruz K., Anguiano-Robledo L., Calzada-Mendoza C.C. et al. von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage. Haemophilia. 2020;26(1):97–105. https://doi.org/10.1111/hae.13900.South K., Freitas M.O., Lane D.A. A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. J Biol Chem. 2018;293(4):1149–50. https://doi.org/10.1074/jbc.M117.776732.South K., Freitas M.O., Lane D.A. A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. J Biol Chem. 2018;293(4):1149–50. https://doi.org/10.1074/jbc.M117.776732.Plautz W.E., Raval J.S., Dyer M.R. et al. ADAMTS13: origins, applications and prospects. Transfusion. 2018;58(10):2453–62. https://doi.org/10.1111/trf.14804.Plautz W.E., Raval J.S., Dyer M.R. et al. ADAMTS13: origins, applications and prospects. Transfusion. 2018;58(10):2453–62. https://doi.org/10.1111/trf.14804.de Groot R., Lane D.A., Crawley J.T. The role of the ADAMTS13 cysteinerich domain in VWF binding and proteolysis. Blood. 2015;125(12):1968–7. https://doi.org/10.1182/blood-2014-08-594556.de Groot R., Lane D.A., Crawley J.T. The role of the ADAMTS13 cysteinerich domain in VWF binding and proteolysis. Blood. 2015;125(12):1968–7. https://doi.org/10.1182/blood-2014-08-594556.Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–8. https://doi.org/10.1182/blood-2013-04-460147.Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–8. https://doi.org/10.1182/blood-2013-04-460147.Katneni U.K., Ibla J.C., Hunt R. et al. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period. J Thromb Haemost. 2019;17(3):429–40. https://doi.org/10.1111/jth.14374.Katneni U.K., Ibla J.C., Hunt R. et al. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period. J Thromb Haemost. 2019;17(3):429–40. https://doi.org/10.1111/jth.14374.Schaller M., Studt J.D., Voorberg J., Kremer Hovinga J.A. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie. 2013;33(2):121–30. https://doi.org/10.5482/HAMO-12-12-0023.Schaller M., Studt J.D., Voorberg J., Kremer Hovinga J.A. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie. 2013;33(2):121–30. https://doi.org/10.5482/HAMO-12-12-0023.De Young V., Singh K., Kretz C.A. Mechanisms of ADAMTS13 regulation. J Thromb Haemost. 2022 Sep 8. https://doi.org/10.1111/jth.15873. Onlineahead of print.De Young V., Singh K., Kretz C.A. Mechanisms of ADAMTS13 regulation. J Thromb Haemost. 2022 Sep 8. https://doi.org/10.1111/jth.15873. Online ahead of print.Sánchez-Aranguren L.C., Prada C.E., Riaño-Medina C.E., Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014;5:372. https://doi.org/10.3389/fphys.2014.00372.Sánchez-Aranguren L.C., Prada C.E., Riaño-Medina C.E., Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014;5:372. https://doi.org/10.3389/fphys.2014.00372.Molvarec A., Rigó J., Bõze T. et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost. 2009;101(2):305–11.Molvarec A., Rigó J., Bõze T. et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost. 2009;101(2):305–11.Aref S., Goda H. Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology. 2013;18(4):237–41. https://doi.org/10.1179/1607845412Y.0000000070.Aref S., Goda H. Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology. 2013;18(4):237–41. https://doi.org/10.1179/1607845412Y.0000000070.Sánchez-Luceros A., Meschengieser S.S., Marchese C. et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis. 2003;14(7):647–5. https://doi.org/10.1097/00001721-200310000-00005.Sánchez-Luceros A., Meschengieser S.S., Marchese C. et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis. 2003;14(7):647–5. https://doi.org/10.1097/00001721-200310000-00005.Grandone E., Vimercati А., Sorrentino F. et al. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis. BMC Pregnancy Childbirth. 2022;22(1):142. https://doi.org/10.1186/s12884-022-04405-8.Grandone E., Vimercati А., Sorrentino F. et al. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis. BMC Pregnancy Childbirth. 2022;22(1):142. https://doi.org/10.1186/s12884-022-04405-8.Reiter R.A., Varadi K., Turecek P.L. et al. Changes in ADAMTS13 (vonWillebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 2005;93:554–8. https://doi.org/10.1160/TH04-08-0467.Reiter R.A., Varadi K., Turecek P.L. et al. Changes in ADAMTS13 (vonWillebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 2005;93:554–8. https://doi.org/10.1160/TH04-08-0467.Strauss T., Elisha N., Ravid B. et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates. Blood Cells Mol Dis. 2017;67:14–7. https://doi.org/10.1016/j.bcmd.2016.12.013.Strauss T., Elisha N., Ravid B. et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates. Blood Cells Mol Dis. 2017;67:14–7. https://doi.org/10.1016/j.bcmd.2016.12.013.Khorana A., Francis C., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.Khorana A., Francis C., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.Palacios-Acedo A.L., Mege D., Crescence L. et al. Platelets, thromboinflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805. https://doi.org/10.3389/fimmu.2019.01805.Palacios-Acedo A.L., Mege D., Crescence L. et al. Platelets, thromboinflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805. https://doi.org/10.3389/fimmu.2019.01805.Mochizuki S., Soejima K., Shimoda M. et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012;104(12):906–22. https://doi.org/10.1093/jnci/djs232.Mochizuki S., Soejima K., Shimoda M. et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012;104(12):906–22. https://doi.org/10.1093/jnci/djs232.Ishihara J., Ishihara A., Starke R.D. et al. The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood. 2019;133(24):2559–69. https://doi.org/10.1182/blood.2019000510.Ishihara J., Ishihara A., Starke R.D. et al. The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood. 2019;133(24):2559–69. https://doi.org/10.1182/blood.2019000510.Guo R., Yang J., Liu X. et al. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small cell lung cancer. J Clin Lab Anal. 2018;32(1):e22219. https://doi.org/10.1002/jcla.22219.Guo R., Yang J., Liu X. et al. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small cell lung cancer. J Clin Lab Anal. 2018;32(1):e22219. https://doi.org/10.1002/jcla.22219.Koh S.C., Razvi K., Chan Y. et al. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet. 2011;284(1):183–90. https://doi.org/10.1007/s00404-010-1605-z.Koh S.C., Razvi K., Chan Y. et al. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet. 2011;284(1):183–90. https://doi.org/10.1007/s00404-010-1605-z.Marfia G., Navone S.E., Fanizzi C. et al. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. Cancer Med. 2016;5(8):1783–90. https://doi.org/10.1002/cam4.747.Marfia G., Navone S.E., Fanizzi C. et al. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. Cancer Med. 2016;5(8):1783–90. https://doi.org/10.1002/cam4.747.Rho J., Ladd J.J., Li C. et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2018;67(3):473–84. https://doi.org/10.1136/gutjnl-2016-312794.Rho J., Ladd J.J., Li C. et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2018;67(3):473–84. https://doi.org/10.1136/gutjnl-2016-312794.Yang A.-J., Wang M., Wang Y. et al. Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. Oncogenesis. 2018;7(1):12. https://doi.org/10.1038/s41389-017-0023-5.Yang A.-J., Wang M., Wang Y. et al. Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. Oncogenesis. 2018;7(1):12. https://doi.org/10.1038/s41389-017-0023-5.Xu Y., Pan S., Liu J. et al. GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature. Oncotarget. 2017;8(66):110517–29. https://doi.org/10.18632/oncotarget.22806.Xu Y., Pan S., Liu J. et al. GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature. Oncotarget. 2017;8(66):110517–29. https://doi.org/10.18632/oncotarget.22806.John A., Robador J.R., Vidal-Y-Sy S. et al. Urothelial carcinoma of the bladder induces endothelial cell activation and hypercoagulation. Mol Cancer Res. 2020;18(7):1099–109. https://doi.org/10.1158/1541-7786.MCR-19-1041.John A., Robador J.R., Vidal-Y-Sy S. et al. Urothelial carcinoma of the bladder induces endothelial cell activation and hypercoagulation. Mol Cancer Res. 2020;18(7):1099–109. https://doi.org/10.1158/1541-7786.MCR-19-1041.Bauer A.T., Suckau J., Frank K. et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153–63. https://doi.org/10.1182/blood-2014-08-595686.Bauer A.T., Suckau J., Frank K. et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153–63. https://doi.org/10.1182/blood-2014-08-595686.O’Sullivan J.M., Preston R.J., Robson T., O’Donnell J.S. Emerging roles for von Willebrand factor in cancer cell biology. Semin Thromb Hemost. 2018;44(2):159–66. https://doi.org/10.1055/s-0037-1607352.O’Sullivan J.M., Preston R.J., Robson T., O’Donnell J.S. Emerging roles for von Willebrand factor in cancer cell biology. Semin Thromb Hemost. 2018;44(2):159–66. https://doi.org/10.1055/s-0037-1607352.Suter C.M., Hogg P.J., Price J.T. et al. Identification and characterisation of a platelet GPIb/V/IX-like complex on human breast cancers: implications for the metastatic process. Jpn J Cancer Res. 2001;92(10):1082–92. https://doi.org/10.1111/j.1349-7006.2001.tb01063.x.Suter C.M., Hogg P.J., Price J.T. et al. Identification and characterisation of a platelet GPIb/V/IX-like complex on human breast cancers: implications for the metastatic process. Jpn J Cancer Res. 2001;92(10):1082–92. https://doi.org/10.1111/j.1349-7006.2001.tb01063.x.Yang X., Sun H., Li Z. et al. Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer. 2015;15:80. https://doi.org/10.1186/s12885-015-1083-6.Yang X., Sun H., Li Z. et al. Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer. 2015;15:80. https://doi.org/10.1186/s12885-015-1083-6.Goertz L., Schneider S.W., Desch A. et al. Heparins that block VEGF-Amediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget. 2016;7(42):68527–45. https://doi.org/10.18632/oncotarget.11832.Goertz L., Schneider S.W., Desch A. et al. Heparins that block VEGF-Amediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget. 2016;7(42):68527–45. https://doi.org/10.18632/oncotarget.11832.Brill A., Fuchs T.A., Savchenko A.S. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136–44. https://doi.org/10.1111/j.1538-7836.2011.04544.x.Brill A., Fuchs T.A., Savchenko A.S. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136–44. https://doi.org/10.1111/j.1538-7836.2011.04544.x.Staessens S., Denorme F., François O. et al. Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. Haematologica. 2020;105(2):498–507. https://doi.org/10.3324/haematol.2019.219881.Staessens S., Denorme F., François O. et al. Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. Haematologica. 2020;105(2):498–507. https://doi.org/10.3324/haematol.2019.219881.Verhenne S., Denorme F., Libbrecht S. et al. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood. 2015;126(14):1715–22. https://doi.org/10.1182/blood-2015-03-632901.Verhenne S., Denorme F., Libbrecht S. et al. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood. 2015;126(14):1715–22. https://doi.org/10.1182/blood-2015-03-632901.Sonneveld M., de Maat M.P.M., Leebeek F.W.G. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systemic review and metaanalysis. Blood Rev. 2014;28(4):167–78. https://doi.org/10.1016/j.blre.2014.04.003.Sonneveld M., de Maat M.P.M., Leebeek F.W.G. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systemic review and metaanalysis. Blood Rev. 2014;28(4):167–78. https://doi.org/10.1016/j.blre.2014.04.003.McCabe D.J., Murphy S.J., Starke R. et al. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci. 2015;348(1–2):35–40. https://doi.org/10.1016/j.jns.2014.10.035.McCabe D.J., Murphy S.J., Starke R. et al. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci. 2015;348(1–2):35–40. https://doi.org/10.1016/j.jns.2014.10.035.Kovacevic K.D., Mayer F.J., Jilma B. et al. Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study. Atherosclerosis. 2019;290:31–6. https://doi.org/10.1016/j.atherosclerosis.2019.09.003.Kovacevic K.D., Mayer F.J., Jilma B. et al. Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study. Atherosclerosis. 2019;290:31–6. https://doi.org/10.1016/j.atherosclerosis.2019.09.003.Andersson H., Siegerink B., Luken B. et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555–60. https://doi.org/10.1182/blood-2011-09-380618.Andersson H., Siegerink B., Luken B. et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555–60. https://doi.org/10.1182/blood-2011-09-380618.Qu L., Jiang M., Qiu W. et al. Assessment of the diagnostic value of plasma levels, activities, and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction. Clin Appl Thromb Hemost. 2016;22(3):252–9. https://doi.org/10.1177/1076029615583347.Qu L., Jiang M., Qiu W. et al. Assessment of the diagnostic value of plasma levels, activities, and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction. Clin Appl Thromb Hemost. 2016;22(3):252–9. https://doi.org/10.1177/1076029615583347.Donkel S.J., Benaddi B., Dippel D.W.J. et al. Prognostic hemostasis biomarkers in acute ischemic stroke: a systematic review. Arterioscler Thromb Vasc Biol. 2019;39(3):360–72. https://doi.org/10.1161/ATVBAHA.118.312102.Donkel S.J., Benaddi B., Dippel D.W.J. et al. Prognostic hemostasis biomarkers in acute ischemic stroke: a systematic review. Arterioscler Thromb Vasc Biol. 2019;39(3):360–72. https://doi.org/10.1161/ATVBAHA.118.312102.Peeling R.W., Heymann D.L., Teo Y.-Y., Garcia P.J. Diagnostics for COVID19: moving from pandemic response to control. Lancet. 2022;399(10326):757–68. https://doi.org/10.1016/S0140-6736(21)02346-1.Peeling R.W., Heymann D.L., Teo Y.-Y., Garcia P.J. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399(10326):757–68. https://doi.org/10.1016/S0140-6736(21)02346-1.Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.Helms J., Tacquard C., Severac F. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. https://doi.org/10.1007/s00134-020-06062-x.Helms J., Tacquard C., Severac F. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. https://doi.org/10.1007/s00134-020-06062-x.Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. https://doi.org/10.1111/jth.14768.Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. https://doi.org/10.1111/jth.14768.Loo J., Spittle D.A., Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76(4):412–20. https://doi.org/10.1136/thoraxjnl-2020-216243.Loo J., Spittle D.A., Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76(4):412–20. https://doi.org/10.1136/thoraxjnl-2020-216243.Cordoro K.M., Reynolds S.D., Wattier R., McCalmont T.H. Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol. 2020;37(3):419–23. https://doi.org/10.1111/pde.14227.Cordoro K.M., Reynolds S.D., Wattier R., McCalmont T.H. Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol. 2020;37(3):419–23. https://doi.org/10.1111/pde.14227.Zuo Y., Yalavarthi S., Shi H. et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020 Apr 14;2020.04.09.20059626. https://doi.org/10.1101/2020.04.09.20059626. Preprint.Zuo Y., Yalavarthi S., Shi H. et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020 Apr 14;2020.04.09.20059626. https://doi.org/10.1101/2020.04.09.20059626. Preprint.Seth R., McKinnon T.A.J., Zhang X.F. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. Am J Physiol Heart Circ Physiol. 2022;322(1):H87–H93. https://doi.org/10.1152/ajpheart.00204.2021.Seth R., McKinnon T.A.J., Zhang X.F. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. Am J Physiol Heart Circ Physiol. 2022;322(1):H87–H93. https://doi.org/10.1152/ajpheart.00204.2021.Favaloro E.J., Henry B.M., Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost. 2021;47(4):400–18. https://doi.org/10.1055/s-0041-1727282.Favaloro E.J., Henry B.M., Lippi G. Increased VWF and decreased ADAMTS13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost. 2021;47(4):400–18. https://doi.org/10.1055/s-0041-1727282.Xu X., Feng Y., Jia Y. et al. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and metaanalysis. Thromb Res. 2022;218:83–98. https://doi.org/10.1016/j.thromres.2022.08.017.Xu X., Feng Y., Jia Y. et al. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and metaanalysis. Thromb Res. 2022;218:83–98. https://doi.org/10.1016/j.thromres.2022.08.017.Бицадзе В.О., Хизроева Д.Х., Гри Ж.-К. и др. Патогенетическое и прогностическое значение воспаления и нарушений в оси ADAMTS13/vWF у больных тяжелой формой COVID-19. Акушерство, Гинекология и Репродукция. 2022;16(3):228–43. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.327.Bitsadze V.O., Khizroeva J.Kh., Gris J.-C. et al. Pathogenetic and prognostic significance of inflammation and altered ADAMTS-13/vWF axis in patients with severe COVID-19. Obstetrics, Gynecology and Reproduction. 2022;16(3):228–43. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.327.

The authors declare that there are no conflicts of interest present.